The story of ALK itself is one of the great sagas of precision oncology. First identified in 1994 as part of an NPM-ALK fusion in non-Hodgkin lymphoma, the gene later achieved fame when the EML4-ALK fusion was discovered in non-small-cell lung cancer in 2007, opening the door to a series of remarkably effective ALK inhibitors such as crizotinib and its successors. ALK can be activated in cancer through several distinct mechanisms: gene fusions that create constitutively active chimeric kinases, activating point mutations, copy-number gains and amplifications, and abnormal transcriptional regulation. Each of these mechanisms is now routinely tested for in clinical laboratories, and each carries a different therapeutic implication. The question raised by ALK ATI is whether this alternative transcript represents a fifth, previously underappreciated route to ALK-driven malignancy, or whether it is a biological curiosity that has been overinterpreted by clinicians hungry for new actionable targets.

The original discovery, reported by Wiesner and colleagues in Nature in 2015, was striking. The researchers found that a subset of melanomas expressed ALK protein without any detectable gene fusion, and traced this expression to an alternative promoter within intron 19. In experimental models, the truncated protein appeared to be phosphorylated, to activate oncogenic signalling pathways, to drive tumour formation, and, tantalisingly, to confer sensitivity to crizotinib. Because the kinase domain remained intact and the inhibitory drugs target that domain, the logic seemed sound: a tumour dependent on ALK ATI signalling might respond to ALK inhibitors even without a fusion. This raised the prospect of a tumour-agnostic biomarker, one that could extend ALK-directed therapy to patients with melanoma, sarcoma and other solid tumours whose cancers lacked canonical ALK rearrangements.

Subsequent laboratory work added layers of intrigue. One study showed that the ALK ATI isoform, in a kinase-activity-dependent manner, induces structural changes in chromatin within the nucleus, suggesting the truncated protein might remodel gene expression programs directly rather than simply relaying signals at the cell surface. Another report found that ALK ATI interacts with the c-Myc oncogene and promotes cancer stem-cell-like properties in sarcoma models, hinting at a role in tumour initiation, metastasis and treatment resistance. More recently, a 2025 study in ovarian high-grade serous carcinoma described a transcriptional variant of ALK that appeared to promote apoptosis, an unexpected and paradoxical finding that complicates any simple story of ALK ATI as a straightforward oncogene. Together, these results painted a picture of a versatile and context-dependent molecule whose effects vary dramatically depending on tumour type and cellular environment.

But the edifice began to crack under the weight of independent replication attempts. As the Spanish review documents in detail, subsequent experiments did not consistently reproduce the original claims of growth-factor-independent transformation or sensitivity to ALK inhibitors. A 2021 study using genomic and experimental evidence concluded that ALK ATI does not predict single-agent sensitivity to ALK inhibitors. In melanoma models expressing the alternative transcript, researchers generally observed low levels of ALK phosphorylation and no selective drug response, undermining the central premise that ALK ATI marks tumours that will benefit from ALK-directed therapy. The discrepancy between the initial excitement and the follow-up data illustrates a familiar pattern in translational cancer research: early findings from a limited set of models can generate hypotheses that broader and more rigorous testing fails to confirm.

The clinical literature on ALK ATI is equally fragmented. Studies across melanoma, sarcoma, ovarian carcinoma and histiocytic neoplasms have been retrospective, have employed heterogeneous assays, and have reported inconsistent prevalence figures and contradictory prognostic associations. In melanoma, where the phenomenon was first described, surveys of primary and metastatic cutaneous tumours confirmed that ALK expression through alternative transcriptional initiation occurs, but its correlation with outcomes has been disputed. In histiocytic neoplasms, a 2026 study reported that ALK ATI drives nuclear ALK expression even in the absence of ALK fusions, adding another layer of complexity to the interpretation of ALK staining in these rare tumours. Meanwhile, isolated case reports, such as a PRKCA-fused blue melanocytoma expressing a truncated ALK isoform, demonstrate that the biology of truncated ALK expression can intersect with other genetic events in unpredictable ways.

Perhaps the most consequential part of the review concerns diagnostics. Standard clinical tests for ALK are simply not designed to detect ALK ATI, and misreading them can lead to dangerous conclusions. ALK immunohistochemistry, which detects the protein regardless of how it is produced, cannot distinguish between expression driven by a fusion, by amplification, by ATI or by aberrant expression in inflammatory conditions such as malakoplakia. Break-apart fluorescence in situ hybridization, which detects physical disruption of the ALK locus, will be negative in ALK ATI because the gene is not rearranged. Confirmation that a tumour expresses ALK ATI requires an RNA-based assay specifically designed to demonstrate transcription initiating from intron 19 and continuing into ALK exons 20 through 29, together with the exclusion of a canonical ALK fusion. Without this molecular rigour, a positive ALK stain in a fusion-negative tumour tells the clinician almost nothing actionable.

The authors’ bottom line is deliberately cautious and carries immediate practical weight for oncologists and pathologists. Current evidence, they conclude, supports ALK ATI as a context-dependent biological phenomenon rather than a validated tumour-agnostic driver or predictive biomarker. In plain terms, finding the transcript in a tumour does not establish that the tumour depends on it, and it certainly does not establish that the patient will benefit from an ALK inhibitor. Accordingly, the review states that ALK-inhibitor treatment should not be selected solely on the basis of ALK ATI outside a clinical trial or a carefully documented individual assessment. This is a direct challenge to any practice of treating ALK-immunopositive, fusion-negative tumours with expensive and toxic targeted drugs on the assumption that the alternative transcript is driving them.

The broader lesson extends beyond a single transcript. Pan-cancer transcriptome analyses have revealed that regulation through alternative promoters is pervasive across the human genome, meaning that many cancer genes likely have truncated or altered isoforms awaiting discovery. Distinguishing passenger transcription from true oncogenic dependence will require the same combination of rigorous functional validation, standardised RNA-based diagnostics and prospective clinical trials that ultimately separated genuine ALK fusions from lookalike findings. For now, ALK ATI stands as a cautionary tale and an open scientific question: a kinase fragment that once promised to widen the reach of precision oncology, and that may yet prove important in specific tumour contexts, but that today remains, in the measured words of the Alicante team, unproven as a basis for treatment decisions.

Subject of Research: The role of the ALK ATI alternative transcript as a potential driver and biomarker in solid tumours

Article Title: ALK ATI in solid tumours: biological evidence, diagnostic challenges, and clinical relevance. a narrative review

Article References: Borregón, M., Algarra, M.-A., & Benítez-Fuentes, J.-D. (2026). ALK ATI in solid tumours: biological evidence, diagnostic challenges, and clinical relevance, a narrative review. Molecular Biology Reports, 53(1), Article 1657. https://doi.org/10.1007/s11033-026-12833-4

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12833-4

Keywords: ALK, ALK ATI, alternative transcription initiation, solid tumours, melanoma, sarcoma, ALK inhibitors, crizotinib, molecular diagnostics, precision oncology, biomarkers, kinase signalling

The E4512 trial enrolled patients diagnosed with surgically resected stage IIA through IIIB ALK-positive NSCLC, confirmed by fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), or next-generation sequencing (NGS). Importantly, participants had to meet strict inclusion criteria, including negative surgical margins ensuring complete tumor removal, an Eastern Cooperative Oncology Group (ECOG) performance status of 0–1 denoting relatively preserved functional status, and no prior exposure to any ALK-targeted therapy. Participants were either assigned to active surveillance or crizotinib administered at a dosage of 250 mg twice daily for up to two years, barring disease recurrence or dose-limiting toxicity.

Over a nearly ten-year recruitment period extending from August 2014 to May 2024, the study accrued 166 evaluable patients, closely aligning with its initial target enrollment. The trial’s recruitment was ultimately halted following the U.S. Food and Drug Administration’s approval of alectinib as adjuvant therapy for resected ALK-positive NSCLC, which became the new standard of care and impacted the clinical equipoise necessary for the continuation of the study.

The primary endpoint of the trial was disease-free survival, a critical measure reflecting the time from surgery until cancer recurrence or death, while secondary endpoints included overall survival and safety profiles. After a median follow-up approaching five years (58.3 months), the data demonstrated no statistically significant difference in median DFS between the crizotinib and observation arms. Specifically, patients receiving crizotinib exhibited a median DFS of 72.8 months, slightly below the 75.1 months observed in the observation group, resulting in a hazard ratio (HR) of 1.06 with a wide confidence interval (90% CI: 0.63–1.77) and a high p-value, underscoring the lack of efficacy.

Overall survival data remain immature with median OS not reached in either arm at the time of reporting. Nonetheless, the hazard ratio for OS favored crizotinib numerically (HR 0.49), yet this finding did not achieve statistical significance (p=0.26), indicative of the need for longer follow-up before any definitive conclusions can be drawn regarding survival benefits.

The safety profile of adjuvant crizotinib mirrored known toxicities from prior metastatic NSCLC studies. Grade 3 adverse events were common, affecting roughly one-third of patients treated, with diarrhea and peripheral edema as the most frequent severe toxicities. Moreover, one patient tragically experienced a grade 4 stroke during treatment. Treatment-related adverse effects necessitated dose reductions in nearly a quarter of patients and led to permanent treatment discontinuation in 25%, highlighting the challenge of managing toxicity in the adjuvant setting where patients are potentially cured and generally asymptomatic.

These findings carry significant clinical and biological implications for the management of early-stage resected ALK-positive NSCLC. While crizotinib has revolutionized care for metastatic ALK-positive NSCLC over the last decade, its application in an adjuvant context appears futile according to this trial’s rigorous data. The lack of DFS benefit suggests that crizotinib’s pharmacodynamic and pharmacokinetic properties, or possibly its CNS penetration, may be inadequate to eradicate micrometastatic disease post-surgery.

In contrast, contemporary advances have established second-generation ALK inhibitors like alectinib as the preferred adjuvant agents, given their more favorable CNS activity and superior efficacy in advanced disease. Indeed, regulatory approval of adjuvant alectinib has set a new clinical standard, underscoring the importance of this study’s early termination and providing a sound rationale for clinicians to avoid crizotinib in this context despite its prior approval in metastatic disease stages.

From a molecular perspective, the heterogeneity of ALK rearrangements and the intrinsic resistance mechanisms may also contribute to the observed lack of effect. The ability of crizotinib to reach and sustain cytotoxic levels in potential sanctuary sites post-surgery might be limited. Furthermore, patient selection based on centralized confirmation of ALK status via robust techniques such as FISH, IHC, and NGS ensures the validity of the study population, yet the intrinsic biology of micrometastatic disease remains a formidable barrier.

This trial also reinforces the critical role of large, cooperative group studies embedded within national research initiatives such as the ALCHEMIST program, which rigorously evaluates the utility of targeted therapies in curative-intent settings. The methodological rigor of E4512, including randomized design, stratification, and comprehensive follow-up, exemplifies the gold standard for biomarker-driven trials aimed at personalized medicine in thoracic oncology.

In summation, the E4512 trial results decisively demonstrate that adjuvant crizotinib confers no DFS benefit in patients with resected early-stage ALK-positive NSCLC and is associated with meaningful toxicity. These findings emphasize the evolving paradigm in management where newer-generation ALK inhibitors, supported by more robust clinical data regarding efficacy and CNS penetration, command frontline use in the adjuvant setting.

This data was formally presented and peer-reviewed at the IASLC 2025 World Conference on Lung Cancer, reinforcing the importance of continued multidisciplinary collaboration and innovation in targeting molecular subsets of lung cancer. Moving forward, therapeutic strategies combining surgery with next-generation targeted agents and potentially immunotherapeutic approaches represent a promising horizon for improving outcomes in ALK-driven thoracic malignancies.

Subject of Research:
Adjuvant targeted therapy for resected ALK-positive non-small cell lung cancer

Article Title:
Crizotinib Fails to Improve Disease-Free Survival as Adjuvant Therapy in Early-Stage ALK-Positive NSCLC: Results from the Phase 3 E4512 Trial

News Publication Date:
September 7, 2025

Web References:
https://www.iaslc.org (International Association for the Study of Lung Cancer)

Keywords:
Lung cancer, non-small cell lung cancer, ALK-positive, crizotinib, adjuvant therapy, disease-free survival, ALK inhibitors, targeted therapy, phase 3 clinical trial, thoracic oncology